Guru Fundamental Report for ELV

Elevance Health (ELV) has been rated 79% by Validea's Low PE Investor model, based on John Neff's strategy which targets firms with persistent earnings growth trading at a discount. As a large-cap value stock in the Insurance sector, ELV passed key metrics including P/E, EPS growth, sales growth, and free cash flow, but notably failed on total return/PE and EPS persistence, placing it just shy of the 80% 'some interest' threshold for the strategy, which historically has demonstrated significant market outperformance.

Analysis

Elevance Health (ELV) has been identified as a large-cap value stock with notable, though not unqualified, strengths according to Validea's quantitative model based on John Neff's investment strategy. The company scored a 79%, placing it just below the 80% threshold that typically signals initial interest from the model. ELV's positive attributes are rooted in its core fundamentals, as it successfully passed screens for its P/E ratio, current and future EPS growth, sales growth, and free cash flow. This indicates the firm is trading at a reasonable valuation while demonstrating robust growth and strong cash generation. However, the analysis also flags two specific weaknesses: ELV failed the tests for 'EPS Persistence' and 'Total Return/PE'. The failure on EPS persistence points to a potential lack of consistent, predictable earnings growth over time, and the low Total Return/PE ratio suggests that the combination of its earnings yield and dividend yield is not compelling enough to meet the stringent requirements of the Neff model.

Key Decisions for Investors

• Investors may consider ELV a potential value holding given its positive signals on P/E, growth, and free cash flow, but should be aware it does not meet all criteria of a classic Neff-style investment.
• It is critical to investigate the reasons behind the 'EPS Persistence' failure to understand potential volatility or cyclicality in the company's earnings track record.
• Given the stock's failure on the 'Total Return/PE' metric, investors should independently assess if ELV's dividend yield and growth prospects offer a sufficient total return to justify an investment relative to its risk profile.
• The 79% score suggests a 'hold and monitor' stance; a material improvement in earnings consistency or a more attractive valuation could turn this into a stronger 'buy' signal according to this specific strategy.